[go: up one dir, main page]

BRPI0813966A8 - Usos de mdl-1 - Google Patents

Usos de mdl-1

Info

Publication number
BRPI0813966A8
BRPI0813966A8 BRPI0813966A BRPI0813966A BRPI0813966A8 BR PI0813966 A8 BRPI0813966 A8 BR PI0813966A8 BR PI0813966 A BRPI0813966 A BR PI0813966A BR PI0813966 A BRPI0813966 A BR PI0813966A BR PI0813966 A8 BRPI0813966 A8 BR PI0813966A8
Authority
BR
Brazil
Prior art keywords
cdm
mdl
antagonists
methods
relates
Prior art date
Application number
BRPI0813966A
Other languages
English (en)
Inventor
E Bigler Michael
J Cua Daniel
Joyce-Shaikh Barbara
H Phillips Joseph
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Publication of BRPI0813966A2 publication Critical patent/BRPI0813966A2/pt
Publication of BRPI0813966A8 publication Critical patent/BRPI0813966A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

USOS DE MDL-1. A presente invenção refere-se a métodos para tratamento de distúrbios de reabsorção óssea com antagonistas de MDL-1.
BRPI0813966A 2007-06-29 2008-06-24 Usos de mdl-1 BRPI0813966A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94731407P 2007-06-29 2007-06-29
PCT/US2008/068042 WO2009006112A1 (en) 2007-06-29 2008-06-24 Mdl-1 uses

Publications (2)

Publication Number Publication Date
BRPI0813966A2 BRPI0813966A2 (pt) 2015-01-06
BRPI0813966A8 true BRPI0813966A8 (pt) 2016-02-10

Family

ID=39712082

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813966A BRPI0813966A8 (pt) 2007-06-29 2008-06-24 Usos de mdl-1

Country Status (10)

Country Link
US (2) US20100221252A1 (pt)
EP (1) EP2176294B1 (pt)
JP (2) JP5171948B2 (pt)
CN (1) CN101802011A (pt)
AU (1) AU2008270710A1 (pt)
BR (1) BRPI0813966A8 (pt)
CA (1) CA2691618A1 (pt)
ES (1) ES2540854T3 (pt)
WO (1) WO2009006112A1 (pt)
ZA (1) ZA201000393B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
WO2011053630A1 (en) * 2009-10-30 2011-05-05 Schering Corporation Uses of a mammalian cytokine
TWI807362B (zh) * 2010-11-30 2023-07-01 日商中外製藥股份有限公司 細胞傷害誘導治療劑
US20130323246A1 (en) * 2011-02-18 2013-12-05 Merck Sharp & Dohme Corp. Use of mdl-1 antagonists to treat spondylarthropathy
US20140227719A1 (en) * 2011-09-23 2014-08-14 Merck Sharp & Dohme Corp Mdl-1 ligand
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
ES2774972T3 (es) * 2011-10-13 2020-07-23 Aerpio Therapeutics Inc Tratamiento de enfermedades oculares
WO2013065708A1 (ja) 2011-10-31 2013-05-10 中外製薬株式会社 重鎖と軽鎖の会合が制御された抗原結合分子
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
CN106459954A (zh) 2014-05-13 2017-02-22 中外制药株式会社 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
BR112018068363A2 (pt) 2016-03-14 2019-01-15 Chugai Seiyaku Kabushiki Kaisha fármaco terapêutico indutor de dano celular para uso em terapia de câncer
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
EP3934617A1 (en) 2019-03-08 2022-01-12 Boehringer Ingelheim International GmbH Anti-il-36r antibody formulations
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
CN115779071B (zh) * 2022-11-04 2024-12-24 济宁医学院附属医院 Mdl-1在制备缺血性脑卒中后脑保护药物中的应用
TW202517686A (zh) * 2023-07-13 2025-05-01 大陸商深圳澤安生物醫藥有限公司 多特異性抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416973B1 (en) * 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
WO2005027848A2 (en) * 2003-09-19 2005-03-31 Barnes-Jewish Hospital Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
TW200738752A (en) * 2006-01-31 2007-10-16 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
CA2685015A1 (en) * 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies

Also Published As

Publication number Publication date
JP2010532369A (ja) 2010-10-07
CN101802011A (zh) 2010-08-11
US20120177647A1 (en) 2012-07-12
JP2012233008A (ja) 2012-11-29
WO2009006112A1 (en) 2009-01-08
CA2691618A1 (en) 2009-01-08
AU2008270710A1 (en) 2009-01-08
EP2176294B1 (en) 2015-05-20
ES2540854T3 (es) 2015-07-14
US20100221252A1 (en) 2010-09-02
ZA201000393B (en) 2014-03-26
BRPI0813966A2 (pt) 2015-01-06
JP5171948B2 (ja) 2013-03-27
EP2176294A1 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
BRPI0813966A8 (pt) Usos de mdl-1
CR20110103A (es) Heteroarilos sustituidos
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
PL3725329T3 (pl) Sposób hamowania resorpcji kości
BR112012013260A2 (pt) dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa
EP2332187A4 (en) PHOSPHOR CONVERSED LED
DE602007012072D1 (de) Orantagonisten
BR112012017051A2 (pt) método para diminuir a imunogenicidade
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
DE112007000518A5 (de) Anlage zur Erzeugung von Elektrizität
NI200900148A (es) COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33536A
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
BRPI1006730A2 (pt) biomateriais de fosfato de cálcio com gálio
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
BRPI0919898A2 (pt) 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3
EP2084185A4 (en) HUMAN ANTIBODIES THAT NEUTRALIZE HUMAN METAPNEUMOVIRUS
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0822012A2 (pt) Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
BRPI0716532A2 (pt) compostos azabicÍclios como inidores de reabsorÇço de monoaminas
IL206359A0 (en) Sulfonamides as orexin antagonists
SE0800742L (sv) Vikttäcke

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.